Peptides binding to the Lck-SH3 and Hck-SH3 domains

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses specific peptides, such as His-Ser-Lys-Arg-Pro-Leu-Pro-Pro-Leu-Pro-Ser-Leu, that bind with high affinity to the SH3 domains of human T-cell tyrosine kinase (Lck) and hematopoietic cell kinase (Hck). By targeting these kinases, the peptides can inhibit binding of viral proteins (such as HIV-1 Nef and Hepatitis C NS5A) and modulate immune responses. These peptides can be used as pharmaceutical agents to treat various viral infections, autoimmune diseases, and to prevent organ transplant rejection.

Use CasesContent extracted from patent full text and abstract with AI.

• Drug development for the treatment of HIV/AIDS by disrupting the interaction between HIV Nef protein and Lck/Hck in immune cells.
• Therapeutics for Hepatitis C, by blocking the virus’s ability to interfere with host immunity.
• Immunosuppressive agents to prevent rejection in organ transplantation.
• Treatments for autoimmune diseases such as multiple sclerosis, lupus, rheumatoid arthritis, and type 1 diabetes.
• Development of cytostatic drugs for cancer therapy by modulating immune cell signaling.
• Use in research to study T-cell signaling and kinase pathways via in vitro kinase assays or activity tests.
• Component in dermatological, ophthalmological, nephrological, and neurological treatments where kinase pathways are implicated.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly specific inhibition of Lck and Hck kinases, leading to targeted modulation of immune responses.
• Potential to treat a wide range of diseases, spanning viral infections, autoimmunity, and cancer.
• Ability to disrupt virus-host protein interactions, reducing viral pathogenesis and improving patient outcomes.
• Novel immunosuppressive mechanism that can reduce or prevent transplant rejection without broad immune suppression.
• Peptides can be synthesized or produced via recombinant DNA, offering flexibility and scalability in production.
• Versatile administration possibilities, including oral, injectable, transdermal, and topical delivery forms.
• Promotes the development of personalized medicines targeting specific kinase-related disease processes.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The peptide His-Ser-Lys-Arg-Pro-Leu-Pro-Pro-Leu-Pro-Ser-Leu (I) is new. An independent claim is also included for complexes of (I) with the SH3 domains of human T-cell tyrosine kinase (Lck) and hematopoietic cell kinase (Hck). ACTIVITY : Anti-HIV; Virucide; Hepatotropic; Neuroprotective; Dermatological; Immunosuppressive; Antidiabetic; Antirheumatic; Antiarthritic; Antithyroid; Antiinflammatory; Ophthalmological; Nephrotropic; Cytostatic. MECHANISM OF ACTION : Human T-cell tyrosine kinase (Lck) inhibitor; Hematopoietic cell kinase (Hck) inhibitor.